GSK wins FDA clearance for wider use of Boostrix

12/8/2008 | CNNMoney

The FDA granted approval for the use of GlaxoSmithKline's Boostrix -- a vaccine against tetanus, diphtheria and whooping cough -- in adults ages 19 to 64. The decision expands GSK's market for the vaccine, which is cleared as a booster for patients ages 10 to 18.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC